TIDMORPH

RNS Number : 0127G

Open Orphan PLC

21 July 2021

21 July 2021

Open Orphan plc

("Open Orphan", the "Company")

Result of Annual General Meeting

Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials , announces that at the Annual General Meeting held at 12 noon today, all resolutions were duly passed.

For further information please contact:

 
 Open Orphan plc                                                          +353 (0) 1 644 0007 
 Cathal Friel, Executive Chairman 
 
 Arden Partners plc (Nominated Adviser 
  and Joint Broker)                                                      +44 (0) 20 7614 5900 
 John Llewellyn-Lloyd / Richard Johnson 
  / Oscair McGrath 
 
 finnCap plc (Joint Broker)                                              +44 (0) 20 7220 0500 
 Geoff Nash / James Thompson/ Richard 
  Chambers 
 
 Davy (Euronext Growth Adviser and Joint 
  Broker)                                                                 +353 (0) 1 679 6363 
 Anthony Farrell 
 
 Walbrook PR (Financial PR                   +44 (0)20 7933 8780 or openorphan@walbrookpr.com 
  & IR) 
 Paul McManus/ Sam Allen/ Louis Ashe-Jepson                         +44 (0)7980 541 893 / +44 
                                                                   (0) 7502 558 258 / +44 (0) 
                                                                                  7747 515393 
 
 

Notes to Editors

Open Orphan plc (London and Euronext: ORPH) is a rapidly growing pharmaceutical service/contract research company that is a world leader in testing vaccines and antivirals using human challenge clinical trials. The company provides services to Big Pharma, biotech and government/public health organisations.

Open Orphan runs challenge studies in London from both its 19-bedroom Whitechapel quarantine clinic, opened in February 2021, and its 24-bedroom QMB clinic which also has a highly specialised virology and immunology laboratory on-site. Open Orphan has a leading portfolio of eight human challenge study models for conditions such as RSV, flu, asthma and COPD. In addition, Open Orphan is also developing the world's first COVID-19 human challenge study model as part of the Human Challenge Programme and has signed a reservation contract with the UK Government for the first three COVID-19 vaccine challenge studies.

Building upon its many years of challenge studies and virology research, the Company is developing an in-depth database of infectious disease progression data. Based on the Company's Disease in Motion(R) platform, this unique dataset includes clinical, immunological, virological and digital (wearable) biomarkers. The Disease in Motion platform has many potential applications across a wide variety of end users including big technology, wearables, pharma and biotech companies. Following COVID-19 there is now a renewed interest and investment in infectious diseases.

Open Orphan's Paris office has been providing biometry, data management and statistics to its many European pharmaceutical clients for over 20 years. For over 15 years, the Company's Netherlands office has been providing drug development consultancy and services, including CMC (chemistry, manufacturing and controls), PK and medical writing, to a broad range of European clients. Both offices are now also fully integrated with the London office and working on challenge study contracts as well as supporting third party trial contracts .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGEAFXFASSFEFA

(END) Dow Jones Newswires

July 21, 2021 07:58 ET (11:58 GMT)

Hvivo (LSE:HVO)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Hvivo Charts.
Hvivo (LSE:HVO)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Hvivo Charts.